Fibrodysplasia Ossificans Progressiva: What Have We Achieved and Where Are We Now? Follow-up to the 2015 Lorentz Workshop

Fibrodysplasia Ossificans Progressiva: What Have We Achieved and Where Are We Now? Follow-up to the 2015 Lorentz Workshop

Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare progressive genetic disease effecting one in a million individuals. During their life, patients with FOP progressively develop bone in the soft tissues resulting in increasing immobility and early death. A mutation in the ACVR1 gene was id...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ruben D. de Ruiter, Bernard J. Smilde, Gerard Pals, Nathalie Bravenboer, Petra Knaus, Ton Schoenmaker, Esmée Botman, Gonzalo Sánchez-Duffhues, Maurizio Pacifici, Robert J. Pignolo, Eileen M. Shore, Marjolein van Egmond, Hans Van Oosterwyck, Frederick S. Kaplan, Edward C. Hsiao, Paul B. Yu, Renata Bocciardi, Carmen Laura De Cunto, Patricia Longo Ribeiro Delai, Teun J. de Vries, Susanne Hilderbrandt, Richard T. Jaspers, Richard Keen, Peter Koolwijk, Rolf Morhart, Jan C. Netelenbos, Thomas Rustemeyer, Christiaan Scott, Clemens Stockklausner, Peter ten Dijke, James Triffit, Francesc Ventura, Roberto Ravazzolo, Dimitra Micha, Elisabeth M. W. Eekhoff
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
fibrodysplasia ossificans progessiva (FOP)
trials
therapy
disease models
inflammation
angiogenesis
Diseases of the endocrine glands. Clinical endocrinology
RC648-665
Acceso en línea:https://doaj.org/article/0fd0baada54340b8bb1355163a563232
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/0fd0baada54340b8bb1355163a563232

Ejemplares similares